Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms REGAIN
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 03 May 2023 Results of post hoc analysis (n=3348) assessing at population and individual patient levels, the sustained response of reduction in migraine headache days in patients with migraine treated with galcanezumab from two 6-month episodic migraine (EM; EVOLVE-1/EVOLVE-2), one 3-month chronic migraine (CM; REGAIN), and one 3-month treatment-resistant migraine (CONQUER) studies, published in the Headache.
  • 12 Jun 2022 Results of post-hoc analysis of three studies (EVOLVE- 1 [NCT02614183] and EVOLVE- 2 [NCT02614196]) and CM (REGAIN [NCT02614261) assessing indirect cost savings with galcanezumab versus (vs.) placebo in episodic migraine (EM) and chronic migraine (CM), due to absence or productivity loss at school/work in the US, presented at the 64th Annual Scientific Meeting of the American Headache Society.
  • 01 May 2022 Results assessing long-term safety and efficacy in the Current Medical Research and Opinion

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top